Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial

D. H. Johnson, D. Paul, K. R. Hande

Research output: Contribution to journalArticle

Abstract

5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients. Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day 1 followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior doxorubicin exposure, II (58%) responded compared with nine of 15 (60%) without prior doxorubicin. Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 7.4 hours in 19 patients, TFL is an active, well-tolerated regimen in metastatic breast cancer.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number1 SUPPL. 3
StatePublished - 1997

Fingerprint

Leucovorin
Paclitaxel
Fluorouracil
Breast Neoplasms
Neutropenia
Doxorubicin
Salvage Therapy
Platelet Transfusion
MCF-7 Cells
Granulocyte Colony-Stimulating Factor
Hospitalization
Cell Line

ASJC Scopus subject areas

  • Oncology

Cite this

Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer : BRE-26, a phase II trial. / Johnson, D. H.; Paul, D.; Hande, K. R.

In: Seminars in Oncology, Vol. 24, No. 1 SUPPL. 3, 1997.

Research output: Contribution to journalArticle

@article{bbee3424537d40f6b42448dad8f9687c,
title = "Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial",
abstract = "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients. Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day 1 followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5{\%}) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4{\%}) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9{\%}) and 18 partial responses (53{\%}) for an overall response rate of 62{\%}. Of the 19 evaluable patients with prior doxorubicin exposure, II (58{\%}) responded compared with nine of 15 (60{\%}) without prior doxorubicin. Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 7.4 hours in 19 patients, TFL is an active, well-tolerated regimen in metastatic breast cancer.",
author = "Johnson, {D. H.} and D. Paul and Hande, {K. R.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer

T2 - BRE-26, a phase II trial

AU - Johnson, D. H.

AU - Paul, D.

AU - Hande, K. R.

PY - 1997

Y1 - 1997

N2 - 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients. Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day 1 followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior doxorubicin exposure, II (58%) responded compared with nine of 15 (60%) without prior doxorubicin. Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 7.4 hours in 19 patients, TFL is an active, well-tolerated regimen in metastatic breast cancer.

AB - 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients. Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day 1 followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior doxorubicin exposure, II (58%) responded compared with nine of 15 (60%) without prior doxorubicin. Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 7.4 hours in 19 patients, TFL is an active, well-tolerated regimen in metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031055728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031055728&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031055728

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -